Related Experiment Video
Updated: Mar 31, 2026
03:40
Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
Published on: April 25, 2025
1.3K
Association Between Bortezomib Therapy and Eyelid Chalazia
Frederick W Fraunfelder1, H Kell Yang2
1Department of Ophthalmology, Mason Eye Institute, University of Missouri School of Medicine, Columbia.
JAMA Ophthalmology
|October 16, 2015
Summary
Bortezomib (a cancer drug) may cause chalazia, which are eyelid bumps. Chalazia often resolved when bortezomib treatment was stopped, suggesting a possible drug association.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacovigilance
Background:
- Spontaneous reports and literature suggest a link between bortezomib and chalazia.
- The National Registry of Drug-Induced Ocular Side Effects and published case reports document this association.
Purpose of the Study:
- To investigate the association between bortezomib use and the development of chalazia.
- To analyze case reports to determine the likelihood of this adverse drug reaction.
Main Methods:
- Systematic review of 24 reported cases of bortezomib-associated chalazia.
- Inclusion of data from the National Registry of Drug-Induced Ocular Side Effects and literature.
- Analysis of patient demographics, treatment duration, and dechallenge/rechallenge outcomes.
Main Results:
- 24 cases of bortezomib-associated chalazia were identified, with a mean patient age of 61 years.
- Chalazia were typically multiple, affecting the upper eyelid, with onset around 98 days of bortezomib therapy.
- Positive dechallenge and rechallenge data were observed in several cases.
Conclusions:
- The association between bortezomib and chalazia is classified as 'possible' per WHO adverse drug reaction criteria.
- Improvement or resolution of chalazia upon bortezomib discontinuation supports the link.
- Temporal relationship and dechallenge/rechallenge data strengthen the evidence for this adverse event.
